文献速递胸部CT

基于增强CT的Delta影像组学特征联合血液学指标预测可切除非小细胞肺癌新辅助免疫化疗后病理完全缓解

Delta-radiomics features combined with haematological index predict pathological complete response after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer.
PubMed 文献 · Clin Radiol · 2025-04-07

本研究回顾性纳入165例IB-IIIB期非小细胞肺癌患者,从新辅助免疫化疗前及术前增强CT提取Delta影像组学特征,结合血液学动态变化构建预测病理完全缓解的模型。Delta影像组学模型与联合模型在训练集AUC分别为0.74和0.788,验证集分别为0.718和0.737,联合模型预测效能优于单一Delta影像组学模型。

要点

  • 新辅助免疫化疗后40%(66/165)患者达病理完全缓解。
  • Delta影像组学评分(OR=8.542)与ΔLMR(OR=2.637)为病理完全缓解独立预测因素。
  • 联合模型预测病理完全缓解的AUC在训练集为0.788、验证集为0.737。

核心结论

  • 基于增强CT的Delta影像组学模型及联合血液学动态变化模型均有助于预测非小细胞肺癌新辅助免疫化疗后的病理完全缓解,联合模型预测效能优于单一Delta影像组学模型。

研究设计与样本

  • 回顾性研究,纳入2021年1月至2023年8月165例IB-IIIB期非小细胞肺癌患者,训练集115例、验证集50例,均接受新辅助免疫化疗后手术。
  • 从新辅助免疫化疗前及术前增强CT肿瘤感兴趣区提取影像组学特征,Delta影像组学特征定义为新辅助免疫化疗前与术前阶段影像组学特征的相对净变化。
  • 采用最小绝对收缩和选择算子筛选特征并计算预测病理完全缓解的影像组学评分,行单因素及多因素逻辑回归筛选病理完全缓解相关因素并构建预测模型。

诊断标准与关键数值

  • Delta影像组学评分预测病理完全缓解的OR=8.542(95% CI:3.367-21.673,P<0.001)。
  • ΔLMR预测病理完全缓解的OR=2.637(95% CI:1.094-6.359,P=0.031)。
  • Delta影像组学模型预测病理完全缓解的AUC在训练集为0.74、验证集为0.718。
  • 联合模型预测病理完全缓解的AUC在训练集为0.788、验证集为0.737。
  • 校准曲线显示联合模型预测值与观察值具有良好一致性;决策曲线分析显示模型具有较高临床实用性。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: This study aimed at assessing the value of enhanced computed tomography (CT)-based delta-radiomics features (Delta-RFs) and Delta-RFs combined with haematological dynamic changes in predicting pathological complete response (PCR) after neoadjuvant immunochemotherapy in non-small cell lung cancer (NSCLC).

MATERIALS AND METHODS: From January 2021 to August 2023, in total, 165 patients with stage IB-IIIB NSCLC (training, n=115, validation, n=50) who received neoadjuvant immunochemotherapy before surgery, were retrospectively enrolled. Radiomic features were extracted from tumour region of interest on pretreatment and pre-operation enhanced CT images. Delta-RFs are defined as the relative net change in radiomics features between pre-neoadjuvant immunochemotherapy and pre-operation stage. The least absolute shrinkage and selection operator was used to ensure optimal feature selection to calculate the radiomics score (Rad-score) for predicting PCR. Univariate and multivariate logistic regression analyses were performed to screen the factors related to PCR and predictive models were then constructed.

RESULTS: Forty percent patients showed PCR (66/165) after neoadjuvant immunochemotherapy. Nine Delta-RFs were selected as the most predictive factors for PCR. Logistic regression analysis showed that the Rad-score (OR = 8.542, 95% CI: 3.367-21.673, P<0.001) and ΔLMR (OR = 2.637, 95% CI: 1.094-6.359, P=0.031) were independent factors associated with PCR. With respect to predicting PCR, the Delta-RF model and the combined model both achieved satisfactory areas under the curve in the training (area under the curve [AUC]: 0.74, 0.788) and the validation was found to be cohort (AUC: 0.718, 0.737). The calibration curve showed that the predicted value of Delta-RF combined with haematological dynamic change model was in good agreement with the observed value. Decision curve analysis represented that the model exhibits high clinical practicability.

CONCLUSIONS: The Delta-RF model based on enhanced CT and the combined model can aid in efficient prediction of PCR after neoadjuvant immunochemotherapy in NSCLC, and the combined model can predict PCR performance better than Delta-RF model alone after neoadjuvant immunochemotherapy.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Xiong D, Li J, Li L, et al. Delta-radiomics features combined with haematological index predict pathological complete response after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer. Clin Radiol. 2025. PMID: 40359608. doi:10.1016/j.crad.2025.106906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。